KR102403388B1 - 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도 - Google Patents

면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도 Download PDF

Info

Publication number
KR102403388B1
KR102403388B1 KR1020177001152A KR20177001152A KR102403388B1 KR 102403388 B1 KR102403388 B1 KR 102403388B1 KR 1020177001152 A KR1020177001152 A KR 1020177001152A KR 20177001152 A KR20177001152 A KR 20177001152A KR 102403388 B1 KR102403388 B1 KR 102403388B1
Authority
KR
South Korea
Prior art keywords
polypeptide
gly
vwf
fold
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177001152A
Other languages
English (en)
Korean (ko)
Other versions
KR20170015513A (ko
Inventor
크리스티앙 두비
Original Assignee
아블린쓰 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아블린쓰 엔.브이. filed Critical 아블린쓰 엔.브이.
Priority to KR1020227012546A priority Critical patent/KR102568585B1/ko
Publication of KR20170015513A publication Critical patent/KR20170015513A/ko
Application granted granted Critical
Publication of KR102403388B1 publication Critical patent/KR102403388B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177001152A 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도 Active KR102403388B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227012546A KR102568585B1 (ko) 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013007 2014-06-16
US201462030817P 2014-07-30 2014-07-30
US62/030,817 2014-07-30
PCT/EP2015/063493 WO2015193326A1 (en) 2014-06-16 2015-06-16 Methods of treating ttp with immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012546A Division KR102568585B1 (ko) 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20170015513A KR20170015513A (ko) 2017-02-08
KR102403388B1 true KR102403388B1 (ko) 2022-06-03

Family

ID=51541255

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177001152A Active KR102403388B1 (ko) 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도
KR1020227012546A Active KR102568585B1 (ko) 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227012546A Active KR102568585B1 (ko) 2014-06-16 2015-06-16 면역글로불린 단일 가변 도메인을 이용한 ttp의 치료 방법 및 그의 용도

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3366305B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102403388B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2915473T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3335724T3 (enExample)
PT (5) PT3335724T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG10201811109PA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
MY204220A (en) * 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2023005661A (es) * 2020-11-18 2023-05-26 Green Cross Corp Variante de adamts13 que tiene actividad o velocidad de escape incrementada contra un autoanticuerpo.
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CN118715246A (zh) * 2021-12-10 2024-09-27 李人浩 结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PL1836500T3 (pl) 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
SI2717905T1 (sl) 2011-06-10 2018-09-28 Baxalta GmbH Obravnava bolezni koagulacije z dajanjem rekombinantnega vwf
PH12014500380A1 (en) 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122825A2 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Haematologica 2008 93(2) 232~239*
Transfusion and Apheresis Science 46 (2012) 343~346*

Also Published As

Publication number Publication date
EP3335723A1 (en) 2018-06-20
ES2831865T3 (es) 2021-06-09
EP3335724A1 (en) 2018-06-20
ES2915473T3 (es) 2022-06-22
JP6688746B2 (ja) 2020-04-28
ES2843642T3 (es) 2021-07-19
PL3332800T3 (pl) 2021-04-19
KR102568585B1 (ko) 2023-08-18
AU2015276237A1 (en) 2017-01-19
EP3154569B1 (en) 2021-04-21
ES2881331T3 (es) 2021-11-29
RU2017100077A3 (enExample) 2018-12-25
KR20220053040A (ko) 2022-04-28
WO2015193326A1 (en) 2015-12-23
US10919980B2 (en) 2021-02-16
RU2019131713A (ru) 2019-11-11
SG11201610488QA (en) 2017-01-27
PT3332800T (pt) 2020-11-19
JP2020097600A (ja) 2020-06-25
PL3335723T3 (pl) 2022-07-18
EP3335724B1 (en) 2022-06-22
AU2015276237B2 (en) 2021-02-25
EP4059513A1 (en) 2022-09-21
US12269893B2 (en) 2025-04-08
EP3335723B1 (en) 2022-03-30
PT3335723T (pt) 2022-05-20
PT3366305T (pt) 2020-12-21
IL249540A0 (en) 2017-02-28
EP3332800A1 (en) 2018-06-13
RU2017100077A (ru) 2018-07-12
US20180155440A1 (en) 2018-06-07
PT3335724T (pt) 2022-08-02
PL3335724T3 (pl) 2022-09-19
HK1256730A1 (en) 2019-10-04
US20180155441A1 (en) 2018-06-07
CA2952103A1 (en) 2015-12-23
HK1258508A1 (en) 2019-11-15
PT3154569T (pt) 2021-06-22
AU2021202747B2 (en) 2024-02-15
US20170210822A1 (en) 2017-07-27
EP3332800B1 (en) 2020-08-26
US10858445B2 (en) 2020-12-08
AU2021202747A1 (en) 2021-05-27
JP7105260B2 (ja) 2022-07-22
NL2013007B1 (en) 2016-07-05
US20180155443A1 (en) 2018-06-07
SG10201811109PA (en) 2019-01-30
CN106559985A (zh) 2017-04-05
US20180155442A1 (en) 2018-06-07
EP3366305A1 (en) 2018-08-29
EP3366305B1 (en) 2020-11-18
RU2704444C2 (ru) 2019-10-28
JP2022160431A (ja) 2022-10-19
EP3154569A1 (en) 2017-04-19
JP2017519762A (ja) 2017-07-20
IL249540B (en) 2021-09-30
PL3366305T3 (pl) 2021-06-14
KR20170015513A (ko) 2017-02-08
PL3154569T3 (pl) 2021-11-02
ES2924199T3 (es) 2022-10-05
HK1256731A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
JP7105260B2 (ja) 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用
JP2024001135A (ja) Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
HK40078326A (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
RU2807602C2 (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
HK1258508B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1256731B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930A1 (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1256730B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1236434B (en) Immunoglobulin single variable domains for use in treating ttp

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211021

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220314

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211021

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220414

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220314

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211221

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200416

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220421

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220414

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220314

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20211221

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200416

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220525

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220526

End annual number: 3

Start annual number: 1

PG1601 Publication of registration